ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search
  • 2019 American Transplant Congress

    Belatacept Treated Patients Experience Improved Health-Related Quality of Life and Lower Symptom Distress Compared to Cyclosporine Treated Patients: An Analysis of the Benefit and Benefit-EXT Cohorts

    M. J. Everly1, I. Purnajo1, J. L. Beaumont1, M. Polinsky2, E. Alemao2

    1Terasaki Research Institute, Los Angeles, CA, 2Bristol Myers Squibb, Princeton, NJ

    *Purpose: New immunosuppressive agents in transplant should not only be efficacious but also help patients feel better (i.e. lower patient reported symptoms and improve health…
  • 2019 American Transplant Congress

    Belatacept Based CNI Free Immunosuppression in Pancreas Transplantation. Results at 4 Years

    J. Chen, J. Fridell, M. Yaqub, T. Taber, D. MIshler, O. Adebiyi, M. Mujtaba, A. Sharfuddin

    Indiana University School of Medicine, Indianapolis, IN

    *Purpose: CNI based Immunosuppression is a well known risk factor for worsening renal function. We report our experience in converting Pancreas Transplant recipients from tacrolimus…
  • 2019 American Transplant Congress

    Racial/Ethnic and Socio-Economic Disparities: Single versus Multi-Organ Transplant Recipients

    C. A. Custer1, K. Ladin2, J. Entwistle3, E. J. Gordon4

    1United Network for Organ Sharing, Richmond, VA, 2Tufts University, Medford, MA, 3Thomas Jefferson University, Washington, DC, 4Northwestern University, Chicago, IL

    *Purpose: Under current deceased donor kidney allocation policy, multi-organ transplant (MOT) candidates often receive priority over single organ transplant (SOT) candidates. We examined the distribution…
  • 2019 American Transplant Congress

    Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Solid Organ Transplant Recipients at an Academic Medical Center

    J. S. Kerr, N. Law, S. Aslam

    Center for Transplantation, University of California, San Diego Health System, La Jolla, CA

    *Purpose: In the United States, the incidence of Clostridium difficile infection (CDI) has increased remarkably and remains a significant burden in the solid organ transplant…
  • 2019 American Transplant Congress

    Myeloid AXL Promotes Cardiac Allograft Vasculopathy

    K. E. Glinton1, X. Yeap1, Z. J. Zhang2, X. Luo3, E. B. Thorp1

    1Pathology, FCVRRI, Northwestern University - Feinberg School of Medicine, Chicago, IL, 2Surgery, Northwestern University - Feinberg School of Medicine, Chicago, IL, 3Duke Transplant Center, Duke University School of Medicine, Durham, NC

    *Purpose: Cardiac Allograft Vasculopathy (CAV) is a significant contributor to long term transplant rejection, despite advances in immunotherapy. Reactivity to alloantigen presentation may occur by…
  • 2019 American Transplant Congress

    Dual Targeting Desensitization with Carfilzomib Plus Lulizumab Significantly Prolongs Kidney Transplant Survival in Allosensitized Nonhuman Primates

    P. M. Schroder, R. Schmitz, Z. Fitch, B. Ezekian, J. Yoon, A. Choi, A. Barbas, F. Leopardi, B. Collins, J. Kwun, S. J. Knechtle

    Department of Surgery, Duke University Medical Center, Durham, NC

    *Purpose: Sensitized patients are difficult to transplant due to pre-formed immunity against MHC antigens; thus, new strategies for desensitization are needed to improve outcomes in…
  • 2019 American Transplant Congress

    Recipient Antibiotics Pretreatment Protects Liver Transplants from Ischemia-Reperfusion Injury via Prostaglandin E2: From Bench-to Bedside

    K. Nakamura, S. Kageyama, T. Ito, H. Hirao, K. Kadono, K. J. Dery, J. Aziz, B. Ke, F. M. Kaldas, R. W. Busuttil, J. W. Kupiec‐Weglinski

    Surgery, Dumont-UCLA Transplant Center, UCLA, Los Angeles, CA

    *Purpose: We and others have reported on benefits of endoplasmic reticulum (ER) stress modulation and autophagy enhancement to mitigate ischemia-reperfusion injury (IRI) in orthotopic liver…
  • 2019 American Transplant Congress

    What Are You Smoking? The Impact of Donor Drug Use on Long Term Survival Post-Transplant

    D. A. Baran1, A. Long1, J. T. Lansinger2, H. Copeland3, J. M. Herre1, W. Old1, G. Zeevi1, C. Barreiro1, C. Kemp1, B. H. Smith1, K. Stelling1, A. Ingemi1, P. Bourassa1, J. Philpott1

    1Sentara Heart Hospital, Norfolk, VA, 2Eastern Virginia Medical School, Norfolk, VA, 3Division of Cardiothoracic Surgery, University of Mississippi Medical Center, Jackson, MS

    *Purpose: Drug use is a common aspect in the history of heart transplant donors. Whether prior or current drug use is associated with inferior post…
  • 2019 American Transplant Congress

    Four-Year Follow Up of Kidney Transplantation Using Alemtuzumab Induction and Belatacept/Sirolimus Maintenance Therapy

    A. Kirk1, H. Xu1, A. Ghali2, A. Mehta2, A. Guasch2

    1Surgery, Duke University, Durham, NC, 2Transplant Center, Emory University, Atlanta, GA

    *Purpose: Kidney transplantation remains limited by the chronic toxicities associated with calcineurin inhibitors (CNIs) and steroids. The objective of this clinical trial was to determine…
  • 2019 American Transplant Congress

    A CMV Vaccine Based on Non-Replicating Lymphocytic Choriomeningitis Virus Vectors Expressing gB and pp65 is Safe and Immunogenic in Healthy Volunteers and Entering a Phase 2 Trial in Kidney Transplant Recipients

    C. N. Kotton1, M. Schwendinger2, G. Thiry3, B. De Vos4, F. De Boever5, G. Leroux-Roels6, A. Lilja7

    1Infectious Diseases Division, Boston, MA, 2Hookipa Biotech AG, Vienna, Austria, 3Hookipa Biotech GmbH, VIenna, Austria, 4Bejamad sprl/bvba, Beersel, Belgium, 5Centrum voor vaccinologie (CEVAC), Gdent, Belgium, 6Centrum voor vaccinologie (CEVAC), Gent, Belgium, 7Hookipa Biotech GmbH, Vienna, Austria

    *Purpose: Cytomegalovirus (CMV) is a significant pathogen in pregnancy and immunocompromised patients. Antiviral prophylaxis is limited by toxicities, recurrent infection, and resistance. A safe and…
  • « Previous Page
  • 1
  • …
  • 176
  • 177
  • 178
  • 179
  • 180
  • …
  • 214
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences